{"id":140033,"date":"2026-11-16T17:57:40","date_gmt":"2026-11-16T22:57:40","guid":{"rendered":"https:\/\/cardiologynownews.org\/?p=140033"},"modified":"2026-11-16T17:57:42","modified_gmt":"2026-11-16T22:57:42","slug":"test-2-treat-care-champions-do-not-significantly-improve-ldl-c-lowering-after-mi-or-pci","status":"publish","type":"post","link":"https:\/\/cardiologynownews.org\/?p=140033","title":{"rendered":"Test 2 Treat: Care Champions Do Not Significantly Improve LDL-C Lowering After MI or PCI"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>Test 2 Treat (T2T) evaluated a hospital-level program to increase inpatient LDL-C testing and a patient-level care champion program to improve LDL-C lowering after hospitalization for MI and\/or PCI.<\/li>\n\n\n\n<li>In the randomized program of 400 patients, LDL-C fell 52.4 mg\/dL with the care champion and 47.5 mg\/dL with usual care (difference -5.0 mg\/dL; 95% CI -13.3 to 3.3; <em>P<\/em>=0.23).<\/li>\n\n\n\n<li>LDL-C was checked within 6 months more often with the care champion (67.5% vs 54.5%), but the proportion with a last LDL-C below 70 mg\/dL did not differ significantly (65.3% vs 63.3%).<\/li>\n\n\n\n<li>In a nonrandomized pre\/post comparison at five health systems, inpatient LDL-C testing rose from 53.8% to 65.4% (<em>P<\/em>=0.002), with no significant change in up-titration of therapy before discharge.<\/li>\n\n\n\n<li>About a third of randomized patients had no follow-up LDL-C value.<\/li>\n<\/ul>\n\n\n\n<p>LDL-C reduction 6 months after myocardial infarction (MI) and\/or percutaneous coronary intervention (PCI) did not differ significantly between patients randomized to usual care and those randomized to an intervention that introduced a &#8220;care champion&#8221;, according to results from the Test 2 Treat (T2T) study. In a separate nonrandomized comparison, inpatient LDL-C testing rose by an absolute 11.6% after a site-tailored hospital intervention. Nishant P. Shah, MD (Duke University School of Medicine, Durham, NC), presented the results at the American Heart Association (AHA) Scientific Sessions on November 9, 2026.<\/p>\n\n\n\n<p>Gaps in LDL-C testing and treatment persist after hospitalization for atherosclerotic cardiovascular disease (ASCVD), the investigators said. In February 2026, <a href=\"https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.125.012622\">Shah and colleagues reported<\/a> that just 42.5% of patients with ASCVD and an LDL-C value, across 16 US academic health systems, had levels less than 70 mg\/dL.<\/p>\n\n\n\n<p>T2T (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06471036\">NCT06471036<\/a>) was funded by Amgen. The Duke Clinical Research Institute coordinated the study and analyzed the data independently. Program 2 randomized 400 patients hospitalized with MI and\/or PCI and an LDL-C of at least 70 mg\/dL at six US health systems. They were assigned 1:1 to a care champion or usual care, both with education. For 6 months, care champions worked remotely to reinforce LDL-C goals and adherence, coordinate follow-up testing, and communicate with outpatient clinicians about titration. They could not prescribe. The primary endpoint was the change in LDL-C from admission to the last follow-up measurement. Follow-up measurements counted if taken within 6 months after discharge, with up to 2 extra months allowed.<\/p>\n\n\n\n<p>Mean age was 64.0 years, and mean admission LDL-C was 117.8 mg\/dL. At discharge, 83.5% of the care-champion arm and 75.5% of the usual-care arm were taking a high-intensity statin.<\/p>\n\n\n\n<p>In the modified intention-to-treat analysis, with multiple imputation for missing values, LDL-C fell by a mean of 52.4 mg\/dL with the care champion and 47.5 mg\/dL with usual care. The difference was -5.0 mg\/dL (95% CI -13.3 to 3.3; <em>P<\/em>=0.23). Adjusted (-5.4 mg\/dL; <em>P<\/em>=0.20) and complete-case (-6.2 mg\/dL; <em>P<\/em>=0.11) analyses were consistent.<\/p>\n\n\n\n<p>LDL-C was checked within 6 months in 67.5% of the care-champion arm and 54.5% with usual care (adjusted OR 1.82; 95% CI 1.18 to 2.79; <em>P<\/em>=0.006). Among patients with a follow-up value, the last LDL-C was below 70 mg\/dL in 65.3% and 63.3% of the study groups, respectively (<em>P<\/em>=0.53). Therapy was up-titrated within 4 weeks of an elevated LDL-C in 16 of 59 patients (27.1%) and 4 of 46 (8.7%), respectively (adjusted OR 4.02; 95% CI 1.15 to 14.0; <em>P<\/em>=0.029).<\/p>\n\n\n\n<p>Program 1 compared adults hospitalized with MI and\/or PCI at five US health systems in the 6 months before (n=1,910) and after (n=1,932) a site-tailored intervention. The intervention combined site gap analyses, inpatient care pathways, and audit and feedback. Inpatient LDL-C testing rose from 53.8% to 65.4% (absolute difference 11.6%; 95% CI 7.2 to 16.1; <em>P<\/em>=0.002). Among patients with LDL-C of at least 70 mg\/dL, up-titration of lipid-lowering therapy before discharge was 70.7% before and 69.2% after the intervention (<em>P<\/em>=0.59).<\/p>\n\n\n\n<p>Limitations listed by the investigators included the nonrandomized design of Program 1, so the rise in testing may reflect changes in practice over time unrelated to the intervention. In Program 2, therapy changes depended on outpatient clinicians, LDL-C was not checked within 6 months in 32.5% of care champion patients and 45.5% of usual care patients, and the intervention lasted 6 months. The results have not been published in a peer-reviewed journal.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/doi.org\/10.1161\/CIR.0000000000001423\">2026 American College of Cardiology (ACC)\/AHA dyslipidemia guideline<\/a> sets an LDL-C goal below 55 mg\/dL for patients with ASCVD at very high risk.<\/p>\n\n\n\n<p>The investigators said further study is needed of a care champion who can prescribe lipid-lowering therapy and order LDL-C tests outside clinician visits.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>LDL-C reduction 6 months after myocardial infarction (MI) and\/or percutaneous coronary intervention (PCI) did not differ significantly between patients randomized to usual care and those randomized to an intervention that introduced a &#8220;care champion&#8221;, according to results from the Test 2 Treat (T2T) study. In a separate nonrandomized comparison, inpatient LDL-C testing rose by an [&hellip;]<\/p>\n","protected":false},"author":40604,"featured_media":140034,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"footnotes":"","_ppma_block_editor_authors":""},"categories":[1093,8],"tags":[1096,47,185],"tmauthors":[1085],"ppma_author":[1031],"class_list":{"0":"post-140033","1":"post","2":"type-post","3":"status-publish","4":"format-aside","5":"has-post-thumbnail","7":"category-aha-2026","8":"category-news","9":"tag-aha-2026","10":"tag-featured","11":"tag-news","12":"post_format-post-format-aside","13":"author-basir-gill"},"authors":[{"term_id":1031,"user_id":40604,"is_guest":0,"slug":"basir-gill","display_name":"Basir Gill","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/05064ea2c277f8906826ab0662151459a584dc4b50046758e59dbf39135256c6?s=96&r=g","avatar_alt":"","avatar_decorative":"","author_category":"1","first_name":"Basir","last_name":"Gill","user_url":"","job_title":"Clinical Specialist, Baim Institute for Clinical Research","description":""}],"_links":{"self":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/140033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/users\/40604"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=140033"}],"version-history":[{"count":1,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/140033\/revisions"}],"predecessor-version":[{"id":140035,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/140033\/revisions\/140035"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/media\/140034"}],"wp:attachment":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=140033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=140033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=140033"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftmauthors&post=140033"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=140033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}